Therapy News and Research

RSS

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.

25 Jul 2011

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

25 Jul 2011

Waters receives CE mark for MassTrak Immunosuppressants XE Kit

Waters Corporation (NYSE: WAT) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus in liver and kidney transplant patients and everolimus in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the management of immunosuppressant drug therapy.

25 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Valeritas' V-Go Disposable Insulin Delivery Device receives CE Mark approval

Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it received CE Mark approval for its V-Go Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification.

25 Jul 2011

Better targeting of pharmaceuticals to patient's genetic profile could save around $110B annually

Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease.

25 Jul 2011

Computer models could fundamentally change the world's healthcare

A massive network of computer programs co-created by University of Manchester scientists could revolutionise healthcare around the world, saving countless lives and billions of pounds.

25 Jul 2011

A Step Ahead Pediatric Therapy partners with The Eisen Agency

A Step Ahead Pediatric Therapy, a comprehensive pediatric rehabilitation practice based in Northern Kentucky, has partnered with premier Cincinnati public relations firm The Eisen Agency. The leading firm will create and implement a campaign designed to build awareness regarding the unique story of A Step Ahead and the importance and value of pediatric therapy.

25 Jul 2011

Study: Mail-order pharmacy use linked to improved cardiovascular risk factor outcomes

Kaiser Permanente Northern California patients who obtained new statin prescriptions via a mail-order pharmacy achieved better cholesterol control in the first 3-15 months following the initiation of therapy -- compared to those patients who only obtained their statin prescription from their local Kaiser Permanente Northern California pharmacy.

25 Jul 2011

Two genetic variations can identify children at higher risk of radiation-induced second cancers

A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment.

25 Jul 2011

New method for detecting breast cancer at 'stage 0'

RNL Natural Co., Ltd, a leading biotech company specialized in adult stem cell therapeutics affiliated with RNL BIO Co., Ltd., introduced on June 22, 2011 a new method of detecting breast cancer as early as at 'stage 0' through breath VOCs.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Reports came in last Wednesday that circumcision reduces transmission of HIV, in regions where transmission is high. To researchers, this procedure proves to be a cost-effective way to handle the pandemic. In South Africa, a study reported that men with circumcisions reduced new HIV infections by 76%.

24 Jul 2011

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

In a unique study, researchers at The Long Island Brain Tumor Center at Neurological Surgery, P.C. are examining whether hyperbaric oxygen therapy - breathing pure oxygen while in a pressurized chamber - may prove a useful addition to the current standard of care for patients newly diagnosed with glioblastoma, an aggressive brain cancer.

22 Jul 2011

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.

22 Jul 2011

Comprehensive and age-appropriate evaluation during hospital stay is best for older patients

Older people rushed to the emergency room are more likely to be living at home up to a year later if they receive a comprehensive and age-appropriate evaluation during their hospital stay.

22 Jul 2011

Elite task force provides insights and guidance on deep brain stimulation for dystonia

Neurologist Michele Tagliati, MD, director of the Movement Disorders Program at Cedars-Sinai Medical Center, served on an elite international task force commissioned by the Movement Disorder Society to provide insights and guidance on deep brain stimulation for dystonia, an uncommon condition that causes sustained, sometimes crippling muscle contractions.

22 Jul 2011

Therapy News and Research

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Waters receives CE mark for MassTrak Immunosuppressants XE Kit

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Valeritas' V-Go Disposable Insulin Delivery Device receives CE Mark approval

Better targeting of pharmaceuticals to patient's genetic profile could save around $110B annually

Computer models could fundamentally change the world's healthcare

A Step Ahead Pediatric Therapy partners with The Eisen Agency

Study: Mail-order pharmacy use linked to improved cardiovascular risk factor outcomes

Two genetic variations can identify children at higher risk of radiation-induced second cancers

New method for detecting breast cancer at 'stage 0'

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Researchers examine benefits of hyperbaric oxygen in treatment of aggressive brain cancer

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Comprehensive and age-appropriate evaluation during hospital stay is best for older patients

Elite task force provides insights and guidance on deep brain stimulation for dystonia

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News